Literature DB >> 26797242

The Reporting of Treatment Nonadherence and Its Associated Impact on Economic Evaluations Conducted Alongside Randomized Trials: A Systematic Review.

Samuel L Brilleman1, Chris Metcalfe2, Tim J Peters3, William Hollingworth2.   

Abstract

OBJECTIVES: To review trial-based economic evaluations, identifying 1) the proportion reporting adherence, 2) methods for assigning intervention costs according to adherence, 3) which participants were included in the economic analysis, and 4) statistical methods to estimate cost-effectiveness in those who adhered. We provide recommendations on handling nonadherence in economic evaluations.
METHODS: The National Health Service Economic Evaluation Database was searched for recently published trials. We extracted information on the methods used to assign shared costs in the presence of nonadherence and methods to account for nonadherence in the economic analysis.
RESULTS: Ninety-six eligible trials were identified. For one-off interventions, 86% reported the number of participants initiating treatment. For recurring interventions, 56% and 73%, respectively, reported the number initiating and completing treatment, whereas 66% reported treatment intensity. Most studies (23 of 31 [74%] trials and 42 of 53 [79%] trials of one-off and recurring interventions, respectively) reported strict intention-to-treat or complete case analyses. A minority (3 of 31 [10%] and 7 of 53 [13%], respectively), however, performed a per-protocol analysis. No studies used statistical methods to adjust for nonadherence directly in the economic evaluation. Only 13 studies described patient-level allocation of intervention costs; there was variation in how fixed costs were assigned according to adherence.
CONCLUSIONS: Most of the trials reported a measure of adherence, but reporting was not comprehensive. A nontrivial proportion of studies report a primary per-protocol analysis that potentially produces biased results. Alongside primary intention-to-treat analysis, statistical methods for obtaining an unbiased estimate of cost-effectiveness in adherers should be considered.
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  adherence; compliance; economic evaluation; systematic review; trial

Mesh:

Year:  2015        PMID: 26797242     DOI: 10.1016/j.jval.2015.07.009

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  3 in total

1.  Cost-effectiveness of telehealth for patients with depression: evidence from the Healthlines randomised controlled trial.

Authors:  Padraig Dixon; Sandra Hollinghurst; Louisa Edwards; Clare Thomas; Alexis Foster; Ben Davies; Daisy Gaunt; Alan A Montgomery; Chris Salisbury
Journal:  BJPsych Open       Date:  2016-08-09

2.  Methods for estimating complier average causal effects for cost-effectiveness analysis.

Authors:  K DiazOrdaz; A J Franchini; R Grieve
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2017-05-24       Impact factor: 2.483

3.  What are the statistical implications of treatment non-compliance in cluster randomized trials: A simulation study.

Authors:  Mirjam Moerbeek; Sander van Schie
Journal:  Stat Med       Date:  2019-10-03       Impact factor: 2.373

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.